Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 9

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer
EP. 2: Differences Between DNA and RNA Testing for NRG1
EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC
EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer
EP. 5: Efficacy With NRG1-Directed Agents in NSCLC
EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer
EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer
EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer
Now Viewing
EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

Related Content:

Fred Hutch Cancer CenterPancreatic Cancer
Dendritic Cell–Based Immunotherapy Data in Resected Pancreatic Cancer Published in JCO
LODER Plus SOC Chemotherapy Elicits Responses, Boosts OS in KRAS+ Unresectable, Locally Advanced Pancreatic Cancer
Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma